A randomised two arm trial of modestly accelerated radiotherapy with synchronous cisplatinum chemotherapy versus conventional radiotherapy with synchronous cisplatinum chemotherapy in the treatment of head and neck squamous cell carcinoma: a pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN86478952

Enrollment

Registered

2004-09-30

Start date

2002-07-05

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer: Head and neck Cancer Head and neck

Interventions

Twelve eligible patients will receive accelerated radiotherapy (six fractions per week, over 5½ weeks to a total dose of 68 Gray). The extra fraction will be given on any day Monday to Friday (prefera

Eligibility

Inclusion criteria

Inclusion criteria: Patients with histologically proven squamous cell carcinoma of the oropharynx hypopharynx larynx or oral cavity (not nasopharynx/sinuses) and fully meet the criteria will be approached for consent. The study requires 12 patients.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Primary end point: to assess tolerability of modestly accelerated radiotherapy with synchronous cisplatin chemotherapy	—

Secondary

Measure	Time frame
1. Disease-free survival 2. Normal tissue toxicity	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026